Promising drug may halt devastating NMOSD attacks faster
NCT ID NCT07184840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether eculizumab can help people having a sudden attack of NMOSD, a rare autoimmune disease that damages the nerves in the eyes and spine. The drug works by blocking part of the immune system to stop nerve injury. About 110 adults who test positive for a specific antibody will receive the drug, and doctors will measure if their disability improves within 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
110 people
The number who actually took part.
- Started
-
Sep 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Anti-AQP4 antibody seropositive. 2. Male or female patients ≥18 years old 3. Body weight ≥ 35 kg 4. Acute optic neuritis and/or transverse myelitis enrolled within 28 days from the attack, with a change in neurological exam that meet an increase of OSIS at least 2 points of baseline compared to that of prior attack. 5. A female subject is eligible to enter the trial if she is: * Not pregnant or breastfeeding, not intending to conceive during the course of the trial Exclusion Criteria: 1. Use of IVIg within 3 weeks prior to screening 2. Unresolved meningococcal infection 3. Any systemic bacterial or other infection which is clinically significant in the opinion of the Investigator and has not been treated with appropriate antibiotics 4. Participation in any other investigational drug study or was exposed to an investigational drug or device within 30 days of screening. 5. Has previously received treatment with eculizumab 6. Hypersensitivity to murine proteins or to one of the excipients of eculizumab 7. Any medical condition that, in the opinion of the Investigator, might interfere with thepatient's participation in the trial, poses any added risk for the patient, or confounds the assessment of the patients
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neuromyelitis optica spectrum disorder attack are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.